Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    Identifying and Optimizing Chemical Threat Countermeasures

    By Global Biodefense StaffMarch 14, 2016
    NIH CounterACT Chemical Countermeasure Program
    Share
    Facebook LinkedIn Reddit Email

    The National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program has released two new funding opportunities to support identification and optimization of therapeutics to treat exposures to chemical warfare agents and toxic industrial chemicals.

    The civilian chemical threat spectrum includes chemical warfare agents (e.g., sarin), toxic industrial chemicals (e.g., cyanide), pesticides (e.g., parathion), and other chemicals.

    NIH CounterACT cooperative agreement projects will support studies to generate the tools, efficacy in an appropriate animal model, and safety and pharmacology data necessary to transition the proposed therapeutics to advanced drug development, regulatory approval, and licensure.

    Identification of Therapeutic Lead Compounds

    PAR-16-129

    Supports research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. Includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data.

    Optimization of Therapeutic Lead Compounds

    PAR-16-128

    The scope of research supported includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans.  It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. A previously identified lead compound is required to be eligible for this funding opportunity.

    Funding for this effort will only support the development of lead compounds that can be used to reduce mortality or serious morbidity during a chemical emergency. The primary focus is on post-exposure efficacy; compounds that are only effective if administered prior to the chemical insult (prophylaxis efficacy) will be of lowest priority.

    Applicants are encouraged to collaborate with laboratories that are already certified and legally authorized to work with restricted chemical agents, such as the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and certain contract research organizations, when applicable.

    Animal Models NIH Request for Proposals
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleScience Moving towArds Research Translation and Therapy (SMARTT)
    Next Article Fibers with Active Nanostructures for Next Generation PPE

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.